Please find information below on the invited Workshops that have been confirmed to-date for ANR2018. This information will be updated as the conference nears.

Immunotherapy Beyond GD2 for the Oncologist: Role of T cells, NK cells, PD1 and the Microenvironment

Wednesday May 9, 2018, 1:00-3:00 PM

The immunotherapy workshop may include optimal preclinical models for immunotherapy, targeting the microenvironment, combination immunotherapies, cellular therapies with NK cells, CAR-T cells, vaccines, ongoing clinical trials, and toxicities.

Exploring T Cell Mediated Anti-Tumor Immune Responses in Neuroblastoma
John Maris, MD (Children’s Hospital of Philadelphia)

Bispecific Antibodies – Protein Engineering for Cancer Cure
Nai-Kong Cheung, MD, PhD (Memorial Sloan Kettering Cancer Center, NY)

Checkpoint Inhibition in Cancer
Ira Mellman, PhD (Genentech Inc.)

CAR T Cells for Neuroblastoma: Progress and Challenges
Crystal Mackall, MD (Stanford University, Stanford CA)

1RG-CART, A CRUK-Sponsored Phase I Trial to Evaluate A Novel Chimeric Antigen Receptor-Transduced Autologous T Cells in Children with Neuroblastoma
John Anderson, PhD (UCL Great Ormond Street Institute of Child Health)

Supported by William Guy Forbeck Research Foundation

New Biomarker Technologies: Descriptive, Prognostic, Predictive?

Wednesday May 9, 2018, 3:30-5:30 PM

This workshop will provide a presentation and discussion of cutting-edge translational biomarker technologies for the study of Neuroblastoma. In the first half, an overview of new technologies for assessing tissue and circulating biomarkers will be presented, beginning with next-generation imaging technologies such as multiplexed ion beam imaging (MIBI) and cytometry by time of flight (CytOF). Technical approaches for liquid biopsies will also be discussed, highlighting different methodologies for the study of circulating tumor DNA (ctDNA), miRNA, CTCs, and other circulating molecules. In the second half, we will narrow our focus to ctDNA biomarkers, and discuss the challenges and opportunities for developing and validating ctDNA assays for clinical use. This will include a group discussion, focusing on opportunities for collaboration and pooling of data, as well as how we should be thinking about clinical utility and the possibility of integrating ctDNA into clinical practice

Comprehensive Enumeration of Immune Cells in Clinical Tissue Biopsies Using MIBI
Michael Angelo, MD, PhD (Stanford University, Stanford CA)

State of The Art with Liquid Biopsies: ctDNA Challenges and Advances
Allison Welsh, PhD (Foundation Medicine, Cambridge MA)

RNA Biomarkers in Circulation
Katleen de Preter, MD (Ghent University, Ghent, Belgium)

Clinical Applications of Circulating Tumor DNA Studies: On Your Mark, Get Set, or Go?
Gudrun Schleiermacher, MD, PhD (Curie Institute, France)

RNA and PostTranslational Control: How Do We Identify Protein Drivers as Targets

Thursday, May 10, 2018, 1:00-3:00 PM

This workshop will explore the roles of altered mRNA translational regulation in cancer development, including how translation control influences adaptive responses to oncogenic stress, as well as pharmacological approaches to target the translation machinery in neuroblastoma.

Targeting the Ribosome to Treat Cancer
Jamie H. D. Cate, PhD (University of California, Berkeley)

The Role of The Cap-Binding Protein, eIF4E in Cancer
Nahum Sonenberg, PhD (McGill University, Montreal) 

Translational Control of The Stress Response in MYCN Amplified Neuroblastoma
Poul Sorensen, MD, PhD (University of British Columbia, Vancouver)

Polysome/Ribosome Profiling to Gain an Understanding of Dysregulated Translational Control in Cancers
Anne Willis, PhD (MRC Toxicology Unit, United Kingdom)

Precision Medicine: Optimal Trial Design, Predictive Biomarkers, Efficacy 

Thursday May 10, 2018, 3:30-5:30 PM

This workshop will examine and discuss challenges and best practices for effectively utilizing genetic information in the design and implementation of clinical trials to support the development of precision medicines, including exploring the potential advantages and disadvantages of such trials in neuroblastoma and across a variety of pediatric cancers.

Biomarker-Driven Trials for Children with Cancer: Neuroblastoma as A Model
Yael Mosse, MD (Children’s Hospital of Philadelphia)

Challenges and Pitfalls in Precision Medicine for Children with Cancer
Gilles Vassal, PhD (Institut Gustave-Roussy, France)

Clinical Trial Design Considerations in The Era of Precision Medicine
Brian Alexander, MD, MPH (Dana-Farber/Harvard Cancer Center)

Innovative Precision Medicine Trials
Donald Berry, PhD (The University of Texas MD Anderson Cancer Center)

Supported by Alex’s Lemonade Stand Foundation for Childhood Cancer

Want to Learn More About Registration?

Click here